GenSpera, Inc. (OTCBB: GNSZ) announced that its patent application, entitled "Tissue Specific Prodrugs," has been issued by the United States Patent and Trademark Office (USPTO) as US Patent 7,767,648. The patent covers the method of use for G-202, GenSpera's lead oncology drug, which is currently in a Phase I clinical study treating cancer patients whose disease has progressed after other treatments.
“The issuance of this patent complements our previously issued composition of matter patent for G-202 and demonstrates our commitment to building a secure IP portfolio for GenSpera”
"The issuance of this patent complements our previously issued composition of matter patent for G-202 and demonstrates our commitment to building a secure IP portfolio for GenSpera," commented Dr. Craig Dionne, Ph.D., GenSpera CEO and President.
G-202 is a prodrug that is selectively activated within tumors by an enzyme present on the tumor blood vessels. In preclinical testing, G-202 was shown to ablate tumors in animal models of breast cancer, prostate cancer and kidney cancer. GenSpera, Inc. owns and controls all rights to G-202 and anticipates a strategic partnership to maximize the value of the drug as it progresses through future clinical trials.
Scientists map cancer mutations in EGFR gene, revealing drug resistance paths